Yang et al. suggested that tRF-315 reduced the sensitivity of prostate cancer cells to cisplatin by targeting the GADD45A gene in prostate cancer cells and regulating apoptosis pathway-related protein expression, to inhibit tumor cell death [83] (Fig. 2e). Here, GADD45A is linked to prostate carcinoma.